There has been considerable controversy over several years regarding the use of cholinesterase inhibitors and memantine for the treatment of Alzheimer’s disease. In a recently published technology appraisal, NICE has reversed previous guidance on the use of these drugs in England and Wales. In this article, aspects of the diagnosis and management of Alzheimer’s disease in the light of this guidance are reviewed.